-
HyperTrap Heparin HP Column for Signaling Workflows
2026-09-11
The HyperTrap Heparin HP Column combines ready-to-use handling with fine-particle, heparin-based selectivity for protein cleanup, enrichment, and signaling-support workflows. Its strongest differentiation is workflow flexibility: researchers can use syringes, pumps, chromatography systems, or connected columns while tuning salt, pH, and temperature for demanding samples.
-
Q-VD-OPh for Caspase and Mitophagy Assays
2026-09-11
Q-VD-OPh helps separate caspase-driven apoptosis from mitochondrial quality-control phenotypes in cell and neurodegeneration workflows. This guide translates Rab14–Parkin mitophagy findings into practical assay design, dosing screens, cryopreservation recovery tests, and troubleshooting strategies.
-
Estradiol and the Receptor–Autophagy Frontier
2026-09-10
Estradiol research is moving from receptor activation to systems-level questions about tissue protection, autophagy, and translational precision. This article examines how 17 beta-estradiol can support mechanistic studies across cardiovascular, renal, and metabolic models while outlining a disciplined strategy for receptor attribution and experimental reproducibility.
-
(+)-Bicuculline: Practical GABAA Workflow
2026-09-10
(+)-Bicuculline is a research-use GABAA receptor antagonist for controlled studies of inhibitory synaptic transmission, neuronal signaling, and synaptic NMDA receptor signaling modulation. This guide focuses on solvent preparation, storage, assay controls, and interpretation limits; the compound is not intended for diagnostic, clinical, or therapeutic use.
-
Estradiol, Autophagy, and Perimenopausal Organ Protection
2026-09-09
A recent study integrates NHANES associations, network pharmacology, and perimenopausal mouse experiments to examine how declining estradiol relates to multi-organ aging. Its central finding is that estrogen receptor-dependent autophagy is associated with reduced fibrosis and improved tissue architecture in the heart, aorta, and kidneys, while also highlighting important limits for translation to hormone therapy.
-
Sodium Nitroprusside in Sex-Specific Hypertension
2026-09-09
Sex differences in angiotensin II-induced hypertension create a compelling translational test case for separating vascular smooth muscle responsiveness from neurohumoral disease drivers. This article shows how Sodium Nitroprusside, a nitric oxide donor, can provide a controlled mechanistic perturbation for sex-aware cardiovascular research while highlighting protocol, interpretation, and product-selection priorities.
-
NAT1–ENO1–Lactate Signaling in Colorectal Cancer
2026-09-08
A 2026 MedComm study identifies NAT1 as a metabolic regulator that restrains ENO1 activity and lactate production in colorectal cancer. The work connects lactate-dependent TRAF6 activation with PD-L1 stabilization, providing a mechanistic explanation for how tumor metabolism can weaken checkpoint immunotherapy.
-
Asunaprevir Workflows for HCV NS3 Protease Research
2026-09-08
Build a defensible enzyme-to-cell workflow around Asunaprevir (BMS-650032), from solvent handling and genotype panels to HCV RNA replication inhibition and orthogonal cell-state readouts. The approach combines product-specific assay planning with a reference-study-inspired strategy for separating target engagement, replication effects, and nonspecific toxicity.
-
Cimetidine in Barrier-Aware Cancer Assays
2026-09-07
Cimetidine can do more than define H2 receptor pharmacology: it can help researchers distinguish receptor effects from permeability, efflux, and intracellular trapping in advanced assays. This article develops a barrier-aware framework for cancer research using recent BBB-model evidence without overstating direct CNS or antitumor conclusions.
-
Dabigatran: A Mechanism-to-Assay Research Framework
2026-09-07
Dabigatran provides a precise way to isolate thrombin biology in coagulation research. This article connects its assay behavior with cardio-cerebrovascular disease research and the mechanistic insights of a major catalpol review.
-
Cy3 NHS ester (non-sulfonated) Protocol Guide
2026-09-05
Cy3 NHS ester (non-sulfonated), SKU A8100, provides an orange fluorescent label for amine-bearing proteins, peptides, and nucleic-acid constructs when organic co-solvents are acceptable. It should not be used for aqueous-only workflows or solvent-sensitive samples without compatibility testing; a sulfonated Cy3 NHS ester is more appropriate when water solubility is required.
-
Heparin sodium in Nanovesicle and Coagulation Assays
2026-09-04
Heparin sodium is both a benchmark glycosaminoglycan anticoagulant and a useful mechanistic variable in cell–nanovesicle experiments. This guide connects anti-factor Xa and activated partial thromboplastin time workflows with heparan sulfate proteoglycan uptake studies, emphasizing controlled dosing, matched controls, and practical troubleshooting.
-
HyperTrap Heparin HP Column for CCR7–Notch1 Assays
2026-09-04
The HyperTrap Heparin HP Column brings high-resolution heparin affinity fractionation to CCR7–Notch1 research. This article shows how to use its biochemical selectivity as part of an orthogonal assay strategy without confusing protein enrichment with direct measurement of cancer stemness.
-
Heparin Sodium and Nanovesicle Translation
2026-09-03
Heparin sodium can do more than benchmark anticoagulation. This thought-leadership guide shows how its defined mechanism, anti-factor Xa activity, and aPTT readouts can help translational researchers interrogate heparan sulfate proteoglycan-dependent nanovesicle uptake while keeping coagulation biology, experimental controls, and clinical limitations clearly separated.
-
Ertugliflozin: From Glucose Transport to Translation
2026-09-03
A translational framework for using Ertugliflozin (PF-04971729) to connect SGLT2 biology, weight-loss research, renal transport assays, and emerging inflammatory applications.